Semaglutide to prevent diabetes after a kidney transplant
Treatments studied
Part of Hormones & metabolism, Kidney & urinary clinical trials.
This trial tests whether the medication semaglutide (often used for diabetes) can prevent the development of new diabetes after a kidney transplant. If you are in the early weeks after a transplant and have risk factors for diabetes, this study might help reduce your chances of developing diabetes later.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You had a kidney transplant (from a living or deceased donor) between 4 and 12 weeks ago
- Your kidney function is stable, with an eGFR above 30 (a standard measure of kidney function)
- You are at risk for diabetes, meaning you have a BMI of 25 or higher, or you have borderline-high blood sugar or A1C levels
- You do not already have diabetes (type 1 or type 2) and are not on blood sugar-lowering medication
- You have not had acute heart problems, a stroke, or a mini-stroke in the last month, and you have no history of pancreatitis or certain thyroid cancers
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called an SGLT2 inhibitor (which helps lower blood sugar) in people who have had a kidney transplant and do not have diabetes. The goal is to see if it can prevent new diabetes from developing after a transplant and help protect the transplanted kidney.
This trial tests semaglutide, a medicine that helps lower blood sugar, in people who develop high blood sugar shortly after a kidney transplant. It may help control blood sugar without harming the transplanted kidney, while also checking safety in this specific group.
This Phase 2 study tests semaglutide (a diabetes and weight-related medicine) to see if it can slow or improve diabetic kidney disease in people with type 1 diabetes. You may be able to join if you have type 1 diabetes for at least 5 years and ongoing signs of kidney damage measured in urine tests.
This trial tests semaglutide (a diabetes/weight-loss medicine) to help prevent weight gain after liver transplant. It is also looking at blood sugar and safety while you continue your transplant medicines.
This study tests if an oral semaglutide pill can reduce liver fat and improve body composition in people who have had a liver transplant and have diabetes. It may help manage weight and blood sugar after transplant.
This study tests whether a weight loss medication (semaglutide) can help manage obesity in people who have had a kidney transplant or are at high risk. It aims to improve health outcomes and prevent further kidney decline.
Hear when a new Kidney Transplant Recipient trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.